1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material: Enskyce™
Desogestrel and Ethinyl Estradiol Tablets USP
0.15 mg/0.03 mg

Manufacturer: Lupin Limited
Pithampur (M.P.) - 454 775
INDIA

Distributor: Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients | CAS
--- | ---
Desogestrel | 54024-22-5
Ethinyl Estradiol USP | 57-63-6

3. HAZARD IDENTIFICATION

Fire and Explosion: Expected to be non-combustible

Health: Oral contraceptives should not be used in women who currently have the following conditions:

- Thrombophlebitis or thromboembolic disorders
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease (current or history)
- Valvular heart disease with complications
- Severe hypertension
- Diabetes with vascular involvement
- Headaches with focal neurological symptoms
- Major surgery with prolonged immobilization
4. FIRST AID MEASURE

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

Overdosage
Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.
5. FIRE FIGHTING MEASURE

Fire and Explosion Hazards  
Assume that this product is capable of sustaining combustion.

Extinguishing Media  
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures  
For single units (packages): No special requirements needed.  
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products  
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions  
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions  
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods  
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling  
No special control measures required for the normal handling of this product.

Storage  
Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86°F) [see USP Controlled Room Temperature].

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical Form

Enskyce Tablets are available in a wallet (NDC 68180-882-11) containing 28 tablets packed in a pouch (NDC 68180-882-11). Such three pouches are packaged in a carton (NDC 68180-882-13).

Each wallet contains 28 film-coated tablets in the following order:

- Each of the 21 light orange, round, biconvex, film-coated tablet contains 0.15 mg of desogestrel and 0.03 mg of ethinyl estradiol USP and is debossed with "LU" on one side and “L21" on the other side.
- Each of the 7 green coloured, round, biconvex, film-coated tablet contains inert ingredients and is debossed with "LU" on one side and “L22” on the other side.

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinoma of the Reproductive Organs and Breasts

Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives.

The risk of having breast cancer diagnosed may be slightly increased among current and recent users of combination oral contraceptives. However, this excess risk appears to decrease over time after discontinuation of combination oral contraceptives and by 10 years after cessation the increased risk disappears. Some studies report an increased risk with duration of use while other studies do not and no consistent relationships have been found with dose or type of steroid. Some studies have found a small increase in risk for women who first use combination oral contraceptives before age 20. Most studies show a similar pattern of risk with combination oral contraceptives regardless of a woman’s reproductive history or her family breast cancer history.

Breast cancers diagnosed in current or previous oral contraceptive users tend to be less clinically advanced than in nonusers.
Women who currently have or have had breast cancer should not use oral contraceptives because breast cancer is usually a hormonally-sensitive tumor.

Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been established.

### 12. ECOLOGICAL INFORMATION

No relevant studies identified.

### 13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

### 14. TRANSPORT INFORMATION

**IATA/ICAO - Not Regulated**
- IATA Proper shipping Name : N/A
- IATA UN/ID No : N/A
- IATA Hazard Class : N/A
- IATA Packaging Group : N/A
- IATA Label : N/A

**IMDG - Not Regulated**
- IMDG Proper shipping Name : N/A
- IMDG UN/ID No : N/A
- IMDG Hazard Class : N/A
- IMDG Flash Point : N/A
- IMDG Label : N/A

**DOT - Not Regulated**
- DOT Proper shipping Name : N/A
- DOT UN/ID No : N/A
- DOT Hazard Class : N/A
- DOT Flash Point : N/A
- DOT Packing Group : N/A
- DOT Label : N/A
15. REGULATORY INFORMATION

This Section Contains Information relevant to compliance with other Federal and/or state laws.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.